Chongqing Precision Biotech Co., Ltd

This early-stage study is testing a new, quickly-made cell therapy for people with severe lupus that hasn't improved with standard drugs. The therapy, called PTOC1, uses the patient's own modified immune cells (CAR-T cells) to target and reduce harmful B cells thought to drive th…

This is an early-stage study testing a new type of CAR-T cell therapy called PIC1 injection for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to standard treatments. The main goal is to check the safety of the treatment and see if it can help control…

This is an early-phase study testing the safety and initial effectiveness of a new type of CAR-T cell therapy for adults with relapsed or hard-to-treat blood cancers, including certain leukemias and lymphomas. Participants will receive a single infusion of these specially enginee…

This early-stage study is testing a new, quickly manufactured cell therapy for people with severe lupus that hasn't improved with standard drugs. Doctors take a patient's own immune cells, modify them in a lab to target harmful B cells thought to drive lupus, and infuse them back…

This is an early-stage study testing a new type of cell therapy called BCMA/CD70 CAR-T for children with severe rheumatic diseases that have not responded to standard treatments. The trial aims to see if this therapy is safe and can reduce disease activity in conditions like juve…

This early-stage study is testing a new type of personalized immune cell therapy (CAR-T) for people with advanced solid tumors that have a specific marker called CD70. The main goals are to find a safe dose and see how the body handles the treatment. It is for adults with cancers…

This is an early-stage trial testing a new type of personalized cell therapy called MC-1-50 for adults with severe, treatment-resistant lupus. The main goal is to check the safety and side effects of three different doses of these specially engineered immune cells. Researchers wi…

This early-stage study is testing a new type of treatment called CAR-T cell therapy for people with advanced cancers that have a specific marker (CEA) and have stopped responding to standard treatments like chemotherapy. The main goals are to find a safe dose and see if the treat…

This early-stage study is testing a new, quickly-made cell therapy for people with severe lupus that hasn't improved with standard drugs. The therapy, called CAR-T, involves taking a patient's own immune cells, modifying them to target lupus-related proteins, and putting them bac…